Global and United States Kidney Cancer Drug Market Size, Status and Forecast 2020-2026
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Kidney Cancer Drug Market Size Growth Rate by Type: 2020 VS 2026
- 1.2.2 Nexavar (Sorafenib)
- 1.2.3 Sutent (Sunitinib)
- 1.2.4 Afinitor (Everolimus)
- 1.2.5 Votrient (Pazopanib)
- 1.2.6 Avastin (Bevacizumab)
- 1.2.7 Inlyta (Axitinib)
- 1.2.8 Torisel (Temsirolimus)
- 1.2.9 Proleukin (Aldesleukin)
- 1.2.10 Other
- 1.3 Market by Application
- 1.3.1 Global Kidney Cancer Drug Market Share by Application: 2020 VS 2026
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Research Center
- 1.3.5 Other
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Kidney Cancer Drug Market Perspective (2015-2026)
- 2.2 Global Kidney Cancer Drug Growth Trends by Regions
- 2.2.1 Kidney Cancer Drug Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Kidney Cancer Drug Historic Market Share by Regions (2015-2020)
- 2.2.3 Kidney Cancer Drug Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Kidney Cancer Drug Players by Market Size
- 3.1.1 Global Top Kidney Cancer Drug Players by Revenue (2015-2020)
- 3.1.2 Global Kidney Cancer Drug Revenue Market Share by Players (2015-2020)
- 3.2 Global Kidney Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Players Covered: Ranking by Kidney Cancer Drug Revenue
- 3.4 Global Kidney Cancer Drug Market Concentration Ratio
- 3.4.1 Global Kidney Cancer Drug Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Drug Revenue in 2019
- 3.5 Key Players Kidney Cancer Drug Area Served
- 3.6 Key Players Kidney Cancer Drug Product Solution and Service
- 3.7 Date of Enter into Kidney Cancer Drug Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer Drug Breakdown Data by Type (2015-2026)
- 4.1 Global Kidney Cancer Drug Historic Market Size by Type (2015-2020)
- 4.2 Global Kidney Cancer Drug Forecasted Market Size by Type (2021-2026)
5 Kidney Cancer Drug Breakdown Data by Application (2015-2026)
- 5.1 Global Kidney Cancer Drug Historic Market Size by Application (2015-2020)
- 5.2 Global Kidney Cancer Drug Forecasted Market Size by Application (2021-2026)
6 North America
- 6.1 North America Kidney Cancer Drug Market Size (2015-2026)
- 6.2 North America Kidney Cancer Drug Market Size by Type (2015-2020)
- 6.3 North America Kidney Cancer Drug Market Size by Application (2015-2020)
- 6.4 North America Kidney Cancer Drug Market Size by Country (2015-2020)
- 6.4.1 United States
- 6.4.2 Canada
7 Europe
- 7.1 Europe Kidney Cancer Drug Market Size (2015-2026)
- 7.2 Europe Kidney Cancer Drug Market Size by Type (2015-2020)
- 7.3 Europe Kidney Cancer Drug Market Size by Application (2015-2020)
- 7.4 Europe Kidney Cancer Drug Market Size by Country (2015-2020)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 7.4.6 Nordic
- 7.4.7 Rest of Europe
8 China
- 8.1 China Kidney Cancer Drug Market Size (2015-2026)
- 8.2 China Kidney Cancer Drug Market Size by Type (2015-2020)
- 8.3 China Kidney Cancer Drug Market Size by Application (2015-2020)
- 8.4 China Kidney Cancer Drug Market Size by Region (2015-2020)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 Southeast Asia
- 8.4.5 India
- 8.4.6 Australia
- 8.4.7 Rest of Asia-Pacific
9 Japan
- 9.1 Japan Kidney Cancer Drug Market Size (2015-2026)
- 9.2 Japan Kidney Cancer Drug Market Size by Type (2015-2020)
- 9.3 Japan Kidney Cancer Drug Market Size by Application (2015-2020)
- 9.4 Japan Kidney Cancer Drug Market Size by Country (2015-2020)
- 9.4.1 Mexico
- 9.4.2 Brazil
10 Southeast Asia
- 10.1 Southeast Asia Kidney Cancer Drug Market Size (2015-2026)
- 10.2 Southeast Asia Kidney Cancer Drug Market Size by Type (2015-2020)
- 10.3 Southeast Asia Kidney Cancer Drug Market Size by Application (2015-2020)
- 10.4 Southeast Asia Kidney Cancer Drug Market Size by Country (2015-2020)
- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 UAE
- 10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
- 11.1 Active Biotech
- 11.1.1 Active Biotech Company Details
- 11.1.2 Active Biotech Business Overview
- 11.1.3 Active Biotech Kidney Cancer Drug Introduction
- 11.1.4 Active Biotech Revenue in Kidney Cancer Drug Business (2015-2020))
- 11.1.5 Active Biotech Recent Development
- 11.2 Amgen
- 11.2.1 Amgen Company Details
- 11.2.2 Amgen Business Overview
- 11.2.3 Amgen Kidney Cancer Drug Introduction
- 11.2.4 Amgen Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.2.5 Amgen Recent Development
- 11.3 Bayer AG
- 11.3.1 Bayer AG Company Details
- 11.3.2 Bayer AG Business Overview
- 11.3.3 Bayer AG Kidney Cancer Drug Introduction
- 11.3.4 Bayer AG Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.3.5 Bayer AG Recent Development
- 11.4 Cipla Limited
- 11.4.1 Cipla Limited Company Details
- 11.4.2 Cipla Limited Business Overview
- 11.4.3 Cipla Limited Kidney Cancer Drug Introduction
- 11.4.4 Cipla Limited Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.4.5 Cipla Limited Recent Development
- 11.5 F. Hoffmann-La Roche
- 11.5.1 F. Hoffmann-La Roche Company Details
- 11.5.2 F. Hoffmann-La Roche Business Overview
- 11.5.3 F. Hoffmann-La Roche Kidney Cancer Drug Introduction
- 11.5.4 F. Hoffmann-La Roche Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.5.5 F. Hoffmann-La Roche Recent Development
- 11.6 Genentech
- 11.6.1 Genentech Company Details
- 11.6.2 Genentech Business Overview
- 11.6.3 Genentech Kidney Cancer Drug Introduction
- 11.6.4 Genentech Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.6.5 Genentech Recent Development
- 11.7 Glaxosmithkline PLC
- 11.7.1 Glaxosmithkline PLC Company Details
- 11.7.2 Glaxosmithkline PLC Business Overview
- 11.7.3 Glaxosmithkline PLC Kidney Cancer Drug Introduction
- 11.7.4 Glaxosmithkline PLC Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.7.5 Glaxosmithkline PLC Recent Development
- 11.8 Novartis AG
- 11.8.1 Novartis AG Company Details
- 11.8.2 Novartis AG Business Overview
- 11.8.3 Novartis AG Kidney Cancer Drug Introduction
- 11.8.4 Novartis AG Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.8.5 Novartis AG Recent Development
- 11.9 Onyx Pharmaceuticals
- 11.9.1 Onyx Pharmaceuticals Company Details
- 11.9.2 Onyx Pharmaceuticals Business Overview
- 11.9.3 Onyx Pharmaceuticals Kidney Cancer Drug Introduction
- 11.9.4 Onyx Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.9.5 Onyx Pharmaceuticals Recent Development
- 11.10 Pfizer
- 11.10.1 Pfizer Company Details
- 11.10.2 Pfizer Business Overview
- 11.10.3 Pfizer Kidney Cancer Drug Introduction
- 11.10.4 Pfizer Revenue in Kidney Cancer Drug Business (2015-2020)
- 11.10.5 Pfizer Recent Development
- 11.11 Abbott Laboratories
- 10.11.1 Abbott Laboratories Company Details
- 10.11.2 Abbott Laboratories Business Overview
- 10.11.3 Abbott Laboratories Kidney Cancer Drug Introduction
- 10.11.4 Abbott Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
- 10.11.5 Abbott Laboratories Recent Development
- 11.12 Aveo Pharmaceuticals
- 10.12.1 Aveo Pharmaceuticals Company Details
- 10.12.2 Aveo Pharmaceuticals Business Overview
- 10.12.3 Aveo Pharmaceuticals Kidney Cancer Drug Introduction
- 10.12.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
- 10.12.5 Aveo Pharmaceuticals Recent Development
- 11.13 Immatics Biotechnologies
- 10.13.1 Immatics Biotechnologies Company Details
- 10.13.2 Immatics Biotechnologies Business Overview
- 10.13.3 Immatics Biotechnologies Kidney Cancer Drug Introduction
- 10.13.4 Immatics Biotechnologies Revenue in Kidney Cancer Drug Business (2015-2020)
- 10.13.5 Immatics Biotechnologies Recent Development
- 11.14 Prometheus Laboratories
- 10.14.1 Prometheus Laboratories Company Details
- 10.14.2 Prometheus Laboratories Business Overview
- 10.14.3 Prometheus Laboratories Kidney Cancer Drug Introduction
- 10.14.4 Prometheus Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
- 10.14.5 Prometheus Laboratories Recent Development
- 11.15 Exelixis
- 10.15.1 Exelixis Company Details
- 10.15.2 Exelixis Business Overview
- 10.15.3 Exelixis Kidney Cancer Drug Introduction
- 10.15.4 Exelixis Revenue in Kidney Cancer Drug Business (2015-2020)
- 10.15.5 Exelixis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Global Kidney Cancer Drug Scope and Market Size
Kidney Cancer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Kidney Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Nexavar (Sorafenib)
Sutent (Sunitinib)
Afinitor (Everolimus)
Votrient (Pazopanib)
Avastin (Bevacizumab)
Inlyta (Axitinib)
Torisel (Temsirolimus)
Proleukin (Aldesleukin)
Other
Market segment by Application, split into
Hospitals
Clinics
Research Center
Other
Based on regional and country-level analysis, the Kidney Cancer Drug market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Kidney Cancer Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Active Biotech
Amgen
Bayer AG
Cipla Limited
F. Hoffmann-La Roche
Genentech
Glaxosmithkline PLC
Novartis AG
Onyx Pharmaceuticals
Pfizer
Abbott Laboratories
Aveo Pharmaceuticals
Immatics Biotechnologies
Prometheus Laboratories
Exelixis